Final announcement & program Joint EFSPI / BBS Webinar: Estimands addendum is final: Anything new for oncology?

Date: Monday, 29th June 2020, 09:00-11:45
Webinar: dial-in details will be communicated to registered participants

After the publication of the final version of the ICH E9 addendum, the BBS jointly with EFSPI would like to offer a half-day webinar on the broad topic of estimands in oncology drug development.
The event will feature talks from statisticians and clinicians in industry, regulatory agencies, and academia.
Initially, this event was planned as a full-day seminar on the Novartis campus. Given the current COVID-19 situation we turn this event into a series of webinars.
If you’d like to attend please fill out the registration form. After registration you will receive a calendar invite with a webex link.
The webinar is free of charge.

The organizing committee members are Evgeny Degtyarev, Kaspar Rufibach, Bibiana Blatna, Marie- Laure Casadebaig, Lynda Grinsted, Lorenzo Guizzaro, Wolfgang Kothny, Giusi Moffa, Hans-Jochen Weber. The event is supported by the European special interest group “Estimands in oncology”, sponsored by PSI and EFSPI, which is also an ASA scientific working group:

Link to recording

Questions from the webinar chat addressed by the members of the organizing committee and panelists

Kaspar Rufibach, Roche, member of BBS board Welcome and scene setting

Anja Schiel, Norwegian Medicines Agency Experience with the estimand framework in oncology

Renaud Capdeville, Novartis Challenges and open questions in hematology: RATIFY

Tina Nielsen, Roche Challenges and open questions in hematology: GALLIUM

Hannes Buchner, Staburo & Ingolf Griebsch, Boehringer Ingelheim Treatment switching: challenges, estimands, and estimators

Stefan Englert, AbbVie Commentary on previous talks taking COVID-19 into account

Sorry, the comment form is closed at this time.